BCR-ABL1 Positive

14 drugs in development·4 companies·0 clinical trials

Drug Pipeline by Phase

Phase 3(10)

Drug	Company
Blinatumomab	Assertio Holdings, Inc. (ASRT)
bosutinib	GH Research PLC (GHRS)
Cytarabine	Assertio Holdings, Inc. (ASRT)
Filgrastim	Assertio Holdings, Inc. (ASRT)
imatinib	GH Research PLC (GHRS)
Liposome-encapsulated Daunorubicin-Cytarabine	Assertio Holdings, Inc. (ASRT)
nilotinib	GH Research PLC (GHRS)
Ponatinib	ENANTA PHARMACEUTICALS INC (ENTA)
Ponatinib Hydrochloride	Assertio Holdings, Inc. (ASRT)
Vincristine	Assertio Holdings, Inc. (ASRT)

Phase 2(2)

Drug	Company
Pegfilgrastim	Assertio Holdings, Inc. (ASRT)
Ponatinib	Assertio Holdings, Inc. (ASRT)

Phase 1(2)

Drug	Company
Cytarabine	Structure Therapeutics Inc. (GPCR)
Vincristine	Structure Therapeutics Inc. (GPCR)

Compare drugs

Blinatumomab vs bosutinib Blinatumomab vs Cytarabine Blinatumomab vs Filgrastim

Deep-dive into BCR-ABL1 Positive

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis